Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

March 2014 Issue of The Ophthalmologist

Register to download

Register here to download any issue of The Ophthalmologist for FREE.


Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Articles featured in this issue

Business & Profession Other

Benchmarking Ophthalmology

| Mark Hillen

Our cataloging of the major eye diseases is insightful, even though impact factor analysis is flawed.

Business & Profession Retina

See the Benefits of a Good Workout

| Mark Hillen

Mice that take exercise exhibit slower retinal degeneration than those that don’t. It could work for people too.

Subspecialties Cornea / Ocular Surface

Dua for the Price of One

| Mark Hillen

The finding that the core of the trabecular meshwork is an extension of Dua’s layer may have significance in understanding and treating glaucoma.

Subspecialties Retina

Statins Protect Elderly Against Macular Degeneration

| Mark Hillen

If you’re aged over 68 years, then statins significantly reduce your risk of developing AMD; it has no impact on younger age groups.

Subspecialties Retina

Aspirin not Linked to AMD

| Mark Hillen

Previous studies linked aspirin use with age-related macular degeneration, but new data suggest otherwise: aspirin is innocent of all charges.

Subspecialties Basic & Translational Research

STAP! Not so fast

| Mark Hillen

The new method to produce stem cells has run into difficulties in the form of image irregularities and the failure of other labs to reproduce the findings.

Subspecialties Glaucoma

All is Not Lost

| Mark Hillen

Vision training can restore some of the sight lost to glaucoma.

Business & Profession Professional Development

Big in Japan

| Mark Hillen

Acucela prices its initial public offering on the Tokyo Stock Exchange at $162M.

Business & Profession Professional Development

Business in Brief

| Mark Hillen

Aflibercept gets approved by NICE, STAAR’s Visian ICL with CentraFLOW gets approved in Japan, and rises and falls in Allergan and Alcon’s revenues.

Business & Profession Professional Development

World Travel for a Write up of Your Work

| Mark Hillen

If you’re a retina specialist, you’ll be more likely than not to see patients with diabetic macular edema (DME) on a daily basis. Lasers and anti-VEGF therapy have transformed outcomes within a generation

Business & Profession Cataract

A Vision Timebomb

| Mark Hillen

Although baby boomers may be in a state of denial regarding their own aging, ophthalmologists know differently. In particular, four diseases of the ageing eye comprise a demographic and economic timebomb.

Business & Profession Professional Development

Why Snellen Must Die

| Mark Blecher

For the sake of our patients and our profession, we need to improve upon the nineteenth-century pictograms that are currently used for visual assessment.

Business & Profession Professional Development

How to Improve Visual Acuity Testing

| Florian Kretz

The Salzburg Reading Desk is one promising approach to standardizing visual assessments for multifocal intraocular lenses.

Subspecialties Retina

Combining Laser and Anti-VEGF for the Treatment of DME

| Stela Vujosevic

Advances in understanding of the therapeutic mechanisms that underpin micropulse laser treatment suggest that protocols for treatment of diabetic macular edema should be integrated.

Subspecialties Business and Innovation

CLASS-y Laser Treats Glaucoma

| Ehud Assia

Transforming complex, invasive and risky glaucoma surgery into a safe, elegant, and precise procedure.

Subspecialties Cornea / Ocular Surface

Reinventing the Eyedrop: the story of Cationorm

| Mark Hillen

Making an optimal eyedrop formulation has always been a major challenge; compromises had to be made. Nanodroplet emulsion technology has changed that. Here’s how.

Subspecialties Glaucoma

Benchmarking Glaucoma

| Mark Hillen

What does analysis of the last five years of literature on glaucoma tell us about the priorities of the field and the major contributors to it?

Subspecialties Other

Glaucoma awareness from a global perspective

| Richard Gallagher

To mark World Glaucoma Week, here are some of the many creative approaches being taken to communicate awareness of the disease around the world.

Business & Profession Professional Development

Top Tips for Travellers

| Andy Davies

Attending conferences, making presentations and sitting on committees is part and parcel of the job for leading ophthalmologists. Here are my tips to make sure you arrive fresh and look the part.

Business & Profession Professional Development

Championing the Will of Wills

Sitting down with Julia Haller, Ophthalmologist-in-Chief, and Joseph Bilson, Chief Executive Officer of the Wills Eye Hospital, Philadelphia, PA, USA.

Other issues of 2014